New drug QRX-3 aims to speed kidney recovery in hospital patients
NCT ID NCT07161843
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the investigational drug QRX-3 can help hospitalized children and adults with acute tubular necrosis, a type of sudden kidney failure. About 500 participants will receive either QRX-3 or a placebo alongside standard care. The main goal is to see if QRX-3 improves kidney function faster than standard treatment alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE RENAL FAILURE (ARF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Neukidney Inc
Rosharon, Texas, 77583, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.